CA
NZ
UK
AU
IND
US
Oil markets opened April in a state of studied ambivalence. WTI crude futures fell more than 2.5% in the first trading session of the month, slipping below $99 per barrel after a March that had delivered one of the most dramatic monthly price surges …
Market Movers:On Tuesday, the top gainers were Apellis Pharmaceuticals, Inc. (+135.40%) and U-BX Technology Ltd. (112.63%). On the contrary, CDT Equity Inc. (-45.45%) and Battalion Oil Corporation (-28.83%) declined the most the same day.
Global financial markets experienced a sharp rebound as investors responded to signs of easing geopolitical tensions. The possibility of reduced disruption in energy markets provided short-term optimism after a prolonged period of stress.
The first quarter of 2026 has emerged as a defining phase for global financial markets, characterized by simultaneous shocks across commodities and equities. The scale and speed of price movements have forced investors to reconsider long-held assumptions about growth, inflation, and asset allocation.
U.S. equity index futures were firmer in early trading, pointing to a flat-to-slightly positive open after a sharp rebound in the prior session. In early pre-market pricing, Dow futures were up roughly 0.4% (about 200 points), with S&P 500 futures up about 0.5% and …
A sea of green swept across the Nasdaq 100 on April 1st 2026, with virtually every major technology and semiconductor name posting significant gains in a rally that analysts attributed to a convergence of three powerful forces: a potential off-ramp from the US-Iran conflict, …
Wars have historically been reliable generators of domestic political solidarity. The rally-round-the-flag effect, documented across decades of conflict from the Gulf War to the immediate aftermath of September 11, typically delivers a president a surge in public approval that can persist for months. The …
On the surface,Nvidia'scurrent situation defies conventional logic. The company just reported fiscal 2026 revenues of approximately $216 billion, a 73% year-on-year surge, and guided for 81% growth in the quarter ahead. Yet its stock has fallen roughly 18% from its all-time high of $212.19, …
The US equity market displayed a highly definitive "risk-on" rotation on Tuesday, March 31, 2026. While previous sessions may have seen investors favoring defensive safe havens, the capital flow has violently reversed. Driven by a resurgence in growth multiples and high-beta risk appetite, the …
Viridian Therapeutics reported positive topline results from its REVEAL-1 Phase 3 trial evaluating subcutaneous elegrobart in active thyroid eye disease (TED). The study met its primary endpoint, with proptosis responder rates reaching 54% in the Q4 weekly dosing arm and 63% in the Q8 …
Please wait processing your request...